Emergent Biosolutions Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$73.6M
Doctors Paid
858
Transactions
38,170
2024 Total
$442,153
Payment Breakdown by Category
Research$71.8M (97.6%)
Consulting$1.4M (1.9%)
Royalty/License$89,718 (0.1%)
Travel$60,548 (0.1%)
Food & Beverage$44,135 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $71.8M | 36,488 | 97.6% |
| Consulting Fee | $1.4M | 610 | 1.9% |
| Honoraria | $129,209 | 50 | 0.2% |
| Royalty or License | $89,718 | 3 | 0.1% |
| Travel and Lodging | $60,548 | 179 | 0.1% |
| Food and Beverage | $44,135 | 830 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,419 | 8 | 0.0% |
| Grant | $3,500 | 2 | 0.0% |
Payments by Type
Research
$71.8M
36,488 transactions
General
$1.8M
1,682 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| VELOCITY: An Anthrax Vaccine Clinical Study | $26.9M | 2 | 31,919 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | $25.5M | 1 | 762 |
| Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study | $2.8M | 0 | 2,980 |
| EBS.AVA.212 | $2.2M | 0 | 55 |
| A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents | $1.6M | 1 | 68 |
| UTMB | $1.4M | 0 | 11 |
| A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], unadjuvanted or alum-adjuvanted) | $1.2M | 1 | 56 |
| EBS-BCV-001 | $1.1M | 0 | 5 |
| SHIG | $918,283 | 0 | 5 |
| CVH-003 | $580,554 | 0 | 3 |
| Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults | $558,548 | 0 | 17 |
| A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults | $530,038 | 1 | 13 |
| Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects | $519,843 | 0 | 13 |
| Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A | $482,123 | 0 | 95 |
| IA-001 | $422,806 | 0 | 66 |
| EBS.AVA.210 | $408,264 | 0 | 106 |
| EBS-SIN-001 | $379,212 | 0 | 2 |
| Study of SIAN Nasal Spray in Healthy Adults | $231,759 | 0 | 3 |
| Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (CholeraVaccine, Live, Oral) in Children 2 to <18 Years of Age | $228,832 | 0 | 21 |
| Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | $204,838 | 1 | 33 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0328 | $197,467 | 0 | 1 |
| Phase 2: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection | $188,310 | 0 | 58 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0327 | $182,505 | 0 | 1 |
| Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | $181,425 | 1 | 13 |
| EBS-NAR-001 | $164,094 | 0 | 3 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0329 | $161,741 | 0 | 1 |
| PXVX-VC-200 | $141,863 | 0 | 8 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0325 | $107,060 | 0 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0319 | $101,442 | 0 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0332 | $89,074 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| James Mccarty, M.d, M.D | Pediatrics | Madera, CA | $1.5M | $0 |
| Dr. Mark Gold, Md, MD | Addiction Medicine | Gainesville, FL | $290,725 | $0 |
| Timothy Babinchak, Md, MD | Infectious Disease | Phoenixville, PA | $134,200 | $0 |
| Christopher Belcher, Md, MD | Pediatric Infectious Diseases | Carmel, IN | $57,854 | $0 |
| Dr. John Niederhuber, M.d, M.D | Surgical Oncology | Falls Church, VA | $50,000 | $0 |
| Dr. Sean Bennett, Md Phd, MD PHD | Research | Charlottesville, VA | $28,900 | $0 |
| Dr. John Adesioye, Md, MD | Anesthesiology | Hillsboro, OH | $27,938 | $0 |
| Bill Mc Carberg, Md, MD | Family Medicine | San Diego, CA | $27,877 | $0 |
| Steven Stanos, Do, DO | Physical Medicine & Rehabilitation | Seattle, WA | $21,457 | $0 |
| Jennifer Caudle, D.o, D.O | Family Medicine | Sewell, NJ | $20,000 | $0 |
| Dr. Kim Erlich, M.d, M.D | Infectious Disease | Burlingame, CA | $17,730 | $0 |
| Dr. Mark Riddle, M.d, M.D | Public Health & General Preventive Medicine | Fpo, AE | $17,570 | $0 |
| Dr. Kathryn Anderson, Md, Phd, MD, PHD | Internal Medicine | Minneapolis, MN | $17,396 | $0 |
| Gregory Poland, M.d, M.D | Internal Medicine | Rochester, MN | $16,850 | $0 |
| David Kleinman, Md, MD | Retina Specialist | Rochester, NY | $16,725 | $0 |
| Dr. Lisa Ferstenberg, Md, MD | Occupational Medicine | Pueblo, CO | $16,100 | $0 |
| Dr. George Avetian, D.o, D.O | Family Medicine | Wilkes Barre, PA | $10,834 | $0 |
| Christopher Vantilburg, Md, MD | Family Medicine | Vancouver, WA | $8,963 | $0 |
| Amesh Adalja, Md, MD | Emergency Medicine | Pittsburgh, PA | $8,000 | $0 |
| Dr. Joshua Lynch, Do, Emt-P, DO, EMT-P | Emergency Medicine | Orchard Park, NY | $7,225 | $0 |
| David Snydman, Md, MD | Infectious Disease | Boston, MA | $7,050 | $0 |
| Dr. Michael Decker, Md, MD | Infectious Disease | Baxter, TN | $6,323 | $0 |
| Orman Hall, Do, DO | Addiction Medicine | Columbus, OH | $6,250 | $0 |
| Kenton Gregory, Md, MD | Cardiovascular Disease | Portland, OR | $6,167 | $0 |
| Michelle Petri, M.d, M.D | Rheumatology | Baltimore, MD | $5,360 | $0 |
Ad
Top Products
- BioThrax $27.6M
- Biothrax $4.8M
Associated Products (14)
Payment Categories
- Food & Beverage $44,135
- Consulting $1.4M
- Travel & Lodging $60,548
- Research $71.8M
- Royalties $89,718
About Emergent Biosolutions Inc.
Emergent Biosolutions Inc. has made $73.6M in payments to 858 healthcare providers, recorded across 38,170 transactions in the CMS Open Payments database. In 2024, the company paid $442,153. The top product by payment volume is BioThrax ($27.6M).
Payments were distributed across 86 medical specialties. The top specialty by payment amount is Pediatrics ($1.5M to 16 doctors).
Payment categories include: Food & Beverage ($44,135), Consulting ($1.4M), Research ($71.8M), Travel & Lodging ($60,548), Royalties ($89,718).
Emergent Biosolutions Inc. is associated with 14 products in the CMS Open Payments database, including BioThrax, Biothrax, and Chikungunya.